The downgrade from Overweight to Neutral and the significant reduction in the price target from $15 to $1.75 by Piper Sandler's analyst Joseph Catanzaro indicate a less favorable outlook for Rain Oncology. This could lead to a negative short-term impact on the stock price as investors may adjust their positions based on the new rating and price target.